RxDoctor Payments Data

Charles Daniel, MD

Urology · Roanoke, VANPI 1134124035

Payments from drug & device makers

What this record shows

This record is dominated by ownership interests: $81,250 of the $94,135 with a category attached, or 86.3%. Roanoke Area Surgical Lasers, LLC accounts for 91.7% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $33,155 and has fallen 99.5% since, to $172 in 2024. Among urology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$94,135in general payments, 2019–2025

Across 103 payments — averaging $913.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Roanoke Area Surgical Lasers, LLC$86K
  • Intuitive Surgical$6K
  • Astellas Pharma US Inc$399
  • Teleflex LLC$207
  • Coloplast$190
  • Myovant Sciences Inc.$171
  • plus $653 from 12 others

What the payments were for

  • Speaking & faculty fees$5,1005%
  • Travel & lodging$2,6713%
  • Food & beverage$1,4852%
  • Education$3,6294%
  • Ownership interest$81,25086%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$94,135 in reported general payments places this provider in the 95th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$323,489
Medicare patients
1,113
Services billed
11,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron66$74,117
GemtesaVibegron48$50,194
Finasteride964$11,594
Tamsulosin Hcl827$11,561
Silodosin26$4,173
Dutasteride110$3,137
Solifenacin Succinate71$2,704
Potassium Citrate ErPotassium Citrate32$2,621
Testosterone42$2,578
Alfuzosin Hcl ErAlfuzosin Hcl110$1,730
Oxybutynin Chloride ErOxybutynin Chloride61$1,573
Trospium Chloride16$773
Chlorthalidone37$713
Terazosin Hcl41$444
Cephalexin88$433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$399$74,11766 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 300 urology providers in Virginia.

Other urology in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →